Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.47 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.47 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.47 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904332 | 0.87 | CA12 (0.65) | KMT2AGPR35KIF18AGAAHTT | |
| SCHEMBL22005940 | 0.84 | TXNRD1 (0.50) | KMT2AGPR35GAAHTTRAB9A | |
| SCHEMBL6564232 | 0.81 | DTYMK (0.54) | KMT2AKIF18AGAAHTTRAB9A | |
| SCHEMBL10423505 | 0.80 | ALDH1A1 (0.60) | GPR35GAACA12CA1CA2 | |
| SCHEMBL2478404 | 0.80 | KMT2A (0.56) | KMT2AKIF18AGAAHTTRAB9A | |
| SCHEMBL2126401 | 0.80 | KMT2A (0.56) | KMT2AKIF18AGAAHTTRAB9A | |
| SCHEMBL28674925 | 0.80 | KIF18A (0.59) | KMT2AKIF18AGAAHTTRAB9A | |
| SCHEMBL11490967 | 0.80 | KMT2A (0.56) | KMT2AKIF18AGAAHTTRAB9A | |
| SCHEMBL20723890 | 0.79 | TXNRD1 (0.55) | KMT2AGPR35GAAHTTRAB9A | |
| SCHEMBL589336 | 0.78 | KMT2A (0.50) | KMT2AKIF18AGAAHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | disclosed |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-04-13 | — | — | US | disclosed |
| CN-111051302-B | Fluoropiperidine compounds as pure 5-HT 6receptor antagonists | 苏文生命科学有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3649124-B1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | disclosed |
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-05-21 | — | — | US | disclosed |
| EP-3649124-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | Suven Life Sciences Limited (IN) | 2020-05-13 | — | — | EP | disclosed |
| CN-111051302-A | As pure 5-HT6Fluoropiperidine compounds as receptor antagonists | 苏文生命科学有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019030641-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-02-14 | — | — | WO | disclosed |
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| CN-101031554-A | Benzoxazine and quinoxaline derivatives and uses | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| EP-1797051-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006037481-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| EP-0363527-A1 | Photographic element comprising benzoxazine or benzothiazine derivatives | AGFA-GEVAERT N.V. (BE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155560-A1 | FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1B | KMT2A 2865/4885GPR35 80/4885KIF18A 3286/4885 |
| US-10973831-B2 | Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists | HTR6, HTR5A, HTR1B | KMT2A 2865/4885GPR35 80/4885KIF18A 3286/4885 |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | XDH, PDHX, HAX1 | KMT2A 998/4885GPR35 1906/4885KIF18A 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.